Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy
使用 mRNA-外泌体工程体内嵌合抗原受体巨噬细胞 (CARM) 用于癌症免疫治疗
基本信息
- 批准号:10740743
- 负责人:
- 金额:$ 56.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-01 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AnimalsAntibodiesAntigen PresentationAntitumor ResponseAutologousBreastBreast Cancer CellBreast Cancer ModelCAR T cell therapyCD8B1 geneCell TherapyCellsClinicalComplexConsumptionDoseEngineeringEpidermal Growth Factor ReceptorExhibitsFaceFlow CytometryGene ExpressionGenerationsGenesHematologic NeoplasmsHumanITGAM geneImmuneImmunocompetentImmunofluorescence ImmunologicImmunologic StimulationIn VitroInfusion proceduresMacrophageMalignant NeoplasmsMapsMediatingMembraneMessenger RNAMetastatic breast cancerMusMyeloid-derived suppressor cellsNaturePathway interactionsPhagocytesPhagocytosisPhenotypePopulationPre-Clinical ModelPreparationProductionReceptor CellRegimenResearchSolidSolid NeoplasmSpatial DistributionSpecificityT cell infiltrationT-LymphocyteTestingTherapeuticTimeToxic effectViral Vectorantigen-specific T cellsantitumor effectcancer immunotherapychimeric antigen receptorchimeric antigen receptor T cellscytokinedesigndraining lymph nodeengineered exosomesexosomeexperimental studyextracellularimmune activationin vivoinnovationinsightinterestlymph nodesmRNA deliverymalignant breast neoplasmmultiphoton microscopynovel strategiespatient derived xenograft modelprogramsprotein expressionreceptorreconstitutiontranscriptome sequencingtranscriptomicstumortumor growthtumor heterogeneitytumor microenvironment
项目摘要
PROJECT SUMMARY
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic
cancers. However, for solid tumors, CAR T cells face challenges including intratumor heterogeneity, dynamic
expression of target receptors, and often the inability for T cells to traffic to tumors to mediate the desired
antitumor effect. In contrast to the lack of T cell infiltrates, many solid tumors are abundant in immune
suppressive myeloid cells including macrophages. Therefore, converting these immune suppressive cells into
tumoricidal phenotype represents a promising strategy for cell-based therapy. There are now strong interest in
generating CAR macrophages in which autologous macrophages are transduced with CAR delivered by viral
vectors ex vivo to enhance their phagocytosis, antigen presentation and cytokine producing capabilities
following re-infusion. However, ex vivo preparation of CAR macrophages is complex, time consuming, and due
to the non-dividing nature of macrophages, is often inefficient. With the recent advances in mRNA-based
therapeutics, it is now possible to reprogram specific immune cell populations in vivo, thus eliminating the
complex ex vivo production of autologous CAR cells. Our present proposal aims to propose an innovative
strategy of generating CAR macrophages in vivo using mRNA-loaded exosomes to treat HER2 receptor
positive breast cancer. This will be the first study to evaluate the feasibility of producing CAR macrophages in
vivo using mRNA delivery platforms and assessing the antitumor efficacy of CAR macrophages for cancer
immunotherapy. We hypothesize that our strategy represents a revolutionary way to produce CAR
macrophages in vivo using CAR mRNA-loaded exosome and offers a promising new approach for cell therapy
against solid tumors. Our previous study showed that we can efficiently produce mRNA-loaded exosomes to
restore protein expression in solid tumors. Furthermore, our preliminary experiments showed that the
exosomes loaded with HER2 CAR mRNA can produce CAR macrophages in vivo with enhanced effector
functions. Our current study will test our overall hypothesis by using the following specific aims. In Aim 1, we
will evaluate the dynamics and toxicity of CAR macrophage production in vivo using CAR mRNA exosomes. In
Aim 2, we will evaluate transcriptomic and functional profiles of in vivo generated CAR macrophages, Finally,
in Aim 3, we will assess the antitumor effect of in vivo generated CAR macrophages against both murine and
human HER2 expressing breast cancer. If successful, our proposed research can overcome a major technical
hurdle that is currently facing cell therapy. The mRNA exosome platform could potentially be expanded to other
CAR constructs and greatly expand the potential utility of cell therapy for breast and other solid cancers.
项目摘要
嵌合抗原受体(CAR)T细胞疗法已经彻底改变了血液病的治疗。
癌的然而,对于实体瘤,CAR T细胞面临挑战,包括肿瘤内异质性、动态变化、肿瘤细胞的增殖和分化。
靶受体的表达,以及T细胞通常无法运输到肿瘤以介导所需的免疫应答。
抗肿瘤作用与缺乏T细胞浸润相反,许多实体瘤具有丰富的免疫调节功能。
抑制性骨髓细胞,包括巨噬细胞。因此,将这些免疫抑制细胞转化为
杀肿瘤表型代表了基于细胞的治疗的有希望的策略。现在人们对
产生CAR巨噬细胞,其中自体巨噬细胞用由病毒递送的CAR转导,
离体载体以增强其吞噬作用、抗原呈递和细胞因子产生能力
再输注后。然而,CAR巨噬细胞的离体制备是复杂的、耗时的并且由于缺乏足够的细胞毒性,因此需要在体外制备CAR巨噬细胞。
与巨噬细胞的非分裂性质相比,通常是低效的。随着最近基于mRNA的
治疗,现在有可能在体内重新编程特定的免疫细胞群,从而消除免疫缺陷。
自体CAR细胞的复杂离体产生。我们目前的建议旨在提出一个创新的
使用装载mRNA的外泌体治疗HER2受体在体内产生CAR巨噬细胞的策略
乳腺癌阳性。这将是第一项评估在大肠杆菌中产生CAR巨噬细胞的可行性的研究。
体内使用mRNA递送平台并评估CAR巨噬细胞对癌症的抗肿瘤功效
免疫疗法。我们假设我们的策略代表了一种革命性的生产CAR的方法,
巨噬细胞体内使用CAR mRNA加载的外泌体,并为细胞治疗提供了有前途的新方法
对抗实体瘤我们之前的研究表明,我们可以有效地生产载有mRNA的外泌体,
恢复实体瘤中的蛋白质表达。此外,我们的初步实验表明,
负载HER2 CAR mRNA的外泌体可以在体内产生CAR巨噬细胞,
功能协调发展的我们目前的研究将通过使用以下具体目标来测试我们的总体假设。目标1:
将使用CAR mRNA外泌体评估体内CAR巨噬细胞产生的动力学和毒性。在
目的2,我们将评估体内产生的CAR巨噬细胞的转录组学和功能谱,最后,
在目的3中,我们将评估体内产生的CAR巨噬细胞对鼠和鼠巨噬细胞的抗肿瘤作用。
表达人HER2的乳腺癌。如果成功,我们提出的研究可以克服一个主要的技术问题,
这是目前细胞治疗面临的最大障碍。mRNA外泌体平台可能会扩展到其他领域。
CAR构建并极大地扩展了乳腺癌和其他实体癌细胞治疗的潜在效用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wen Jiang其他文献
Wen Jiang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wen Jiang', 18)}}的其他基金
Affinity purification of cross-ß fibrils using immobilized thioflavin
使用固定化硫代黄素对交叉原纤维进行亲和纯化
- 批准号:
10646061 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
A Phagocytosis Modulating Nanomedicine for Targeted Breast Cancer Immunotherapy
用于靶向乳腺癌免疫治疗的吞噬调节纳米药物
- 批准号:
10381905 - 财政年份:2021
- 资助金额:
$ 56.78万 - 项目类别:
Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody
使用新型双特异性抗体靶向治疗多个胶质母细胞瘤吞噬检查点
- 批准号:
10428596 - 财政年份:2021
- 资助金额:
$ 56.78万 - 项目类别:
Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody
使用新型双特异性抗体靶向治疗多个胶质母细胞瘤吞噬检查点
- 批准号:
10212046 - 财政年份:2021
- 资助金额:
$ 56.78万 - 项目类别:
Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody
使用新型双特异性抗体靶向治疗多个胶质母细胞瘤吞噬检查点
- 批准号:
10609925 - 财政年份:2021
- 资助金额:
$ 56.78万 - 项目类别:
Renal Cell Carcinoma Surveillance by Immuno-Lipoplex Nanoparticle Platform
通过免疫脂质体纳米颗粒平台监测肾细胞癌
- 批准号:
10544876 - 财政年份:2020
- 资助金额:
$ 56.78万 - 项目类别:
Renal Cell Carcinoma Surveillance by Immuno-Lipoplex Nanoparticle Platform
通过免疫脂质体纳米颗粒平台监测肾细胞癌
- 批准号:
10044277 - 财政年份:2020
- 资助金额:
$ 56.78万 - 项目类别:
A Phagocytosis Modulating Nanomedicine for Targeted Breast Cancer Immunotherapy
用于靶向乳腺癌免疫治疗的吞噬调节纳米药物
- 批准号:
9805697 - 财政年份:2019
- 资助金额:
$ 56.78万 - 项目类别:
HBGA receptors in host cell entry and infection of norovirus
HBGA受体在诺如病毒进入宿主细胞和感染中的作用
- 批准号:
9182813 - 财政年份:2014
- 资助金额:
$ 56.78万 - 项目类别:
HBGA receptors in host cell entry and infection of norovirus
HBGA受体在诺如病毒进入宿主细胞和感染中的作用
- 批准号:
8967560 - 财政年份:2014
- 资助金额:
$ 56.78万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 56.78万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 56.78万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 56.78万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 56.78万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别: